One hypothesis is that lymphopenia may reflect a state of T cell dysfunction resulting from immune exhaustion and depletion of antitumor lymphocytes, and that these dysfunctional lymphocytes have a limited ability to exert an anti-tumor effect in the setting of PD-1 inhibitor therapy [32]. Here, PDCD1 is linked to lymphopenia.